Chemomab Therapeutics Ltd. (CMMB) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Chemomab Therapeutics Ltd. (CMMB) Earnings Overview
As of June 28, 2026, Chemomab Therapeutics Ltd. (CMMB) reported trailing twelve-month net income of -$9M, reflecting +54.5% year-over-year growth. The company earned $-1.15 per diluted share over the past four quarters.
Looking at the long-term picture, CMMB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2016.
Chemomab Therapeutics Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($349M net income, 22.7% margin), ARDX (-$58M net income, -15.1% margin), PRTA (-$151M net income, -2520.6% margin), CMMB has comparable earnings metrics. Compare CMMB vs HALO →
CMMB Earnings vs Peers
Earnings metrics vs comparable public companies
CMMB Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$9M | +35.5% | -$10M | $-1.42 | - | - |
| 2024 | -$14M | +42.4% | -$15M | $-3.12 | - | - |
| 2023 | -$24M | +12.4% | -$25M | $-8.22 | - | - |
| 2022 | -$28M | -121.6% | -$29M | $-9.68 | - | - |
| 2021 | -$12M | -109.7% | -$12M | $-4.80 | - | - |
| 2020 | -$6M | +78.1% | -$6M | $-25.21 | - | - |
| 2019 | -$27M | -97.2% | -$20M | $-63.20 | - | - |
| 2018 | -$14M | -40.7% | -$13M | $-87.09 | - | - |
| 2017 | -$10M | -107.2% | -$9M | $-875.98 | - | - |
| 2016 | -$5M | +36.9% | -$5M | $-69.00 | - | - |
| 2015 | -$8M | - | -$7M | $-131.76 | - | - |
Download Data
Export CMMB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CMMB — Frequently Asked Questions
Quick answers to the most common questions about buying CMMB stock.
What is CMMB earnings per share (EPS)?
CMMB trailing twelve-month (TTM) diluted EPS is $-1.15, reflecting +54.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Chemomab Therapeutics Ltd.'s net income?
Chemomab Therapeutics Ltd. (CMMB) trailing twelve-month net income is $-9M as of 2025. Earnings grew +54.5% year-over-year.
Is CMMB profitable?
CMMB is not currently profitable on a TTM basis, reporting a net loss of $-9M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CMMB's earnings growth rate?
CMMB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are CMMB's profit margins?
Chemomab Therapeutics Ltd. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -69.5%.
Is CMMB growing earnings?
Yes, CMMB earnings are accelerating — EPS growth of +54.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-9M. Earnings momentum is strengthening.
What was CMMB's best earnings year?
Chemomab Therapeutics Ltd.'s highest annual net income on record is $-5M, achieved in fiscal year 2016. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were CMMB's earnings last quarter?
CMMB's most recent reported quarter was Q4 2025. Net income was $-2M with diluted EPS of $-0.24. For a full breakdown of all quarters, see the quarterly earnings table on this page.